carnitine supplement in end-stage liver disease adult patients
Not Applicable
- Conditions
- liver cirrhosis.K74- Fibrosis and cirrhosis of liver › 2022 ICD-10-CM Diagnosis Code K74.69.K74.60 - A
- Registration Number
- IRCT20200628047940N2
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Adult patients(18-50 years old)
Cirrhotic patients
Exclusion Criteria
Overt hepatic encephalopathy
Consumption of L-carnitine supplement in the last year
Hepatocellular carcinoma
Decompensated cirrhosis
MELD more than 20
HbA1c more than7
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ?Fraility. Timepoint: before intervention, after 2 months. Method of measurement: Liver frailty index. The liver frailty index will be used in the evaluation of frailty in patients with cirrhosis. This criterion consists of three parts. The Frilati Liver Index consists of three performance-based tests (grip strength, chair stands, and balance), a tool that measures physical function specifically in patients with cirrhosis.
- Secondary Outcome Measures
Name Time Method Hepatic encephalopathy. Timepoint: Before intervention and 2, months after intervention. Method of measurement: Clinical examination, and lab data.;Creatinine level. Timepoint: before intervention, and 2 months after intervention. Method of measurement: lab data.